Influenza Clinical Trial
Official title:
A Phase III, Observer-Blind, Randomized, Multi-Center Study to Evaluate Safety, Tolerability and Immunogenicity (in a Subset) Following a Single Intramuscular Dose of a Trivalent Subunit Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs, in Healthy Adult and Elderly Subjects Who Received Either One or the Other Vaccine One Year Before in the V58P4 Study.
Verified date | August 2019 |
Source | Novartis |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of the study is to evaluate safety, tolerability and immunogenicity (in a subset) following a dose of a trivalent subunit influenza vaccine produced either in mammalian cells or in embryonated hen eggs, in healthy adult and elderly subjects who received either vaccine one year before (2004) in the study V58P4.
Status | Completed |
Enrollment | 2235 |
Est. completion date | April 2006 |
Est. primary completion date | December 2005 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. 18 to < 61 years of age (first age group) OR 61 years of age and older (second age group) at enrolment in V58P4 2. Mentally competent to understand the nature, the scope and the consequences of the study 3. Able and willing to give written informed consent prior to study entry 4. Available for all the visits scheduled in the study 5. in good health as determined by: 1. Medical history related to the previous six months, 2. Physical examination, 3. Clinical judgment of the investigator. Exclusion Criteria: 1. Unwilling or unable to give written informed consent to participate in the study 2. Currently experiencing an acute infectious disease 3. Any serious disease such as, for example: 1. Cancer (except for benign or localized skin cancer and non metastatic prostate cancer not currently treated with chemotherapy) 2. Autoimmune disease (including rheumatoid arthritis) 3. Advanced arteriosclerotic disease or complicated diabetes mellitus 4. Chronic obstructive pulmonary disease (COPD) requiring oxygen therapy 5. Acute or progressive hepatic disease 6. Acute or progressive renal disease 7. Congestive heart failure 4. Surgery planned during the study period 5. Bleeding diathesis 6. History of hypersensitivity to any component of the study medication or chemically related substances, such as allergy to eggs or egg products 7. Known or suspected impairment/alteration of immune function resulting from: 1. Receipt of immunosuppressive therapy (any cortical steroid or cancer chemotherapy) 2. Receipt of immunostimulants 3. Receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivatives within the past 3 months and for the full length of the study 4. High risk for developing an immunocompromising disease 8. History of drug or alcohol abuse 9. Laboratory confirmed influenza disease in the past 6 months 10. Received influenza vaccine within the past 6 months 11. Received another vaccine or any investigational agent within the past 60 days, or expect to receive another vaccine within 3 weeks following the study vaccination 12. Participation in another clinical trial within 90 days prior to enrollment and throughout the full length of the study 13. Any acute respiratory disease or infections requiring systemic antibiotic or antiviral therapy (chronic antibiotic therapy for urinary tract prophylaxis is acceptable) or experienced fever _ 38°C within the past 5 days 14. Pregnant/ breast feeding women or women who refuse to use a reliable contraceptive method during the first three weeks after vaccination 15. Any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives. |
Country | Name | City | State |
---|---|---|---|
Poland | NZOZ Jagiello_skie | Centrum Medyczne Sp. Z O.o., O_. Jagiello_skie 1 | Kraków |
Poland | NZOZ Praktyka Grupowa Lekarzy Rodzinnych, "Familia" Sp. z o.o. | Pl. Sikorskiego 6a | Kraków |
Poland | Wojewódzki Szpital Dzieci_cy | Ul. Langiewicza 2 | Kielce |
Poland | Szpital Jana Pawla II, Oddz. Neuroinfekcji | Ul. Pr_dnicka 80 | Kraków |
Poland | Centrum Bada_ Farmakologii Klinicznej | Ul. Ujastek 3 | Krakow |
Lead Sponsor | Collaborator |
---|---|
Novartis Vaccines | Novartis Vaccines and Diagnostics S.r.l. |
Poland,
Szymczakiewicz-Multanowska A, Lattanzi M, Izu A, Casula D, Sparacio M, Kovacs C, Groth N. Safety assessment and immunogenicity of a cell-culture-derived influenza vaccine in adults and elderly subjects over three successive influenza seasons. Hum Vaccin I — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Subjects Reporting Solicited Adverse Events After One Dose of Cell Culture-derived or the Egg-derived Influenza Vaccine | To assess the safety and tolerability in terms of number of adult and elderly subjects reporting solicited adverse events following one dose of the cTIV or the TIV vaccine . | Day 1 to Day 7 postvaccination | |
Secondary | Six-months Safety Data of Subjects After One Dose of Cell Culture Derived or Egg-derived Influenza Vaccine | To collect additional safety data for 6 months after vaccination with one dose of cell culture derived or egg-derived influenza vaccine in terms of serious adverse events (SAEs), adverse events (AEs) necessitating a physician's visit and/or resulting in premature subject's withdrawal from study. | Up to 6 months postvaccination | |
Secondary | Geometric Mean Titers (GMTs) After One Dose of Cell Culture-derived or the Egg-derived Influenza Vaccine in Adult and Elderly Subjects | The haemagglutinin inhibition (HI) antibody titer response following one 0.5 mL dose of either cell derived (cTIV) or egg-derived vaccine (TIV) in adult and elderly subjects is reported as GMTs. The HI GMTs were evaluated using egg-derived antigen assay. |
Day 22 postvaccination | |
Secondary | Geometric Mean Ratios (GMRs), After One Dose of the Cell Culture-derived or the Egg-derived Influenza Vaccine in Adult and Elderly Subjects | Immunogenicity was assessed in terms of GMR in adult and elderly subjects following one 0.5ml dose of either the cTIV vaccine or the TIV vaccine, according to the CHMP criteria. The European licensure (CHMP) criteria was met if the mean geometric increase (GMR, day 22/day 1) in HI antibody titer is >2.5 for adults and >2.0 for elderly subjects. |
Day 22 postvaccination | |
Secondary | Percentages of Adult and Elderly Subjects Achieving HI Titers = 40 After One Dose of the Cell Culture-derived or the Egg-derived Influenza Vaccine. | Immunogenicity was assessed in terms of percentages of adult and elderly subjects achieving HI titers=40,after one dose of either the cTIV vaccine or the TIV vaccine. European (CHMP) criteria is met if the percentage of subjects achieving HI titers = 40 is > 70% for adults and >60% for elderly. |
Day 22 postvaccination | |
Secondary | Percentages of Adult and Elderly Subjects With Seroconversion or Significant Increase in HI Antibody Titers After One Dose of Cell Culture-derived or the Egg-derived Influenza Vaccine. | Immunogenicity was assessed in terms of percentages of adult and elderly subjects showing seroconversion or significant increase in HI antibody titers after one dose of cell culture-derived or the egg-derived influenza vaccine. Seroconversion or significant increase as per European Licensure (CHMP) criteria is defined as percentage of subjects with a prevaccination HI titer <10 to a postvaccination titer = 40 for adults and = 30 for elderly. Significant increase is defined as percentage of subjects with a prevaccination HI titer = 10 and a = 4-fold increase in postvaccination HI antibody titer. |
Day 22 postvaccination |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05523089 -
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
|
Phase 2 | |
Completed |
NCT05009251 -
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
|
N/A | |
Completed |
NCT03282240 -
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
|
Phase 3 | |
Completed |
NCT00968539 -
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT00971425 -
Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)
|
Phase 3 | |
Completed |
NCT00968526 -
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT05525494 -
Patient Portal Flu Vaccine Reminders (5)
|
N/A | |
Completed |
NCT04074928 -
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
|
Phase 3 | |
Completed |
NCT04695717 -
This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam
|
Phase 3 | |
Completed |
NCT05012163 -
Lottery Incentive Nudges to Increase Influenza Vaccinations
|
N/A | |
Completed |
NCT04109222 -
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
|
Phase 4 | |
Completed |
NCT03888989 -
Response to Influenza Vaccine During Pregnancy
|
Phase 1 | |
Completed |
NCT02587221 -
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
|
Phase 3 | |
Completed |
NCT03453801 -
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection
|
Phase 1 | |
Completed |
NCT01440387 -
A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older
|
Phase 3 | |
Terminated |
NCT01195779 -
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
|
Phase 2 | |
Completed |
NCT03321968 -
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
|
Phase 3 | |
Completed |
NCT00972517 -
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
|
Phase 3 | |
Completed |
NCT04570904 -
Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
|
||
Recruiting |
NCT03331991 -
Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel
|
N/A |